REFERENCE:-
1- Yu M C,
Yuan J M,
Govindarajan S,
Ross R K.
Epidemiology of hepatocellular carcinoma.
Can J Gastrenterol.
2000,
14 (8): 703 – 709.
2- Seong J,
Keum KC,
Han KH,
Lee DY,
Lee JT,
Chon CY,
Moon YM,
Suh CO,
Kim GE.
Combined Transcatheter arterial Chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma.
Int J Radiat Oncol Biol phys.
1999,
43 (2): 393 – 397.
3- Parkin DM,
Bray F,
Ferlay J,
Pisani P.
Global cancer statistics.
CA cancer J clin 2002; 55 : 74 – 108,
2005.
4- Bruix J,
Sherman M,
Llovet JM,
Beaugrand M,
Lencioni R,
Burroughs AK,
Christensen E,
Pagliaro L,
Colombo M,
Rodés J; EASL Panel of Experts on HCC.
Clinical management of hepatocellular carcinoma.
Conclusions of the Barcelona-2000 EASL conference.
European Association for the Study of the Liver.
J Hepatol.
2001; 35 (3) : 421 – 430.
5- Peng ZW,
Zhang YJ,
Chen MS,
Xu L,
Liang HH,
Lin XJ,
Guo RP,
Zhang YQ,
Lau WY.
Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma prospective randomized trial.
J Clin Oncol.
2013; 31 : 426 – 432.
6- Zhu AX,
Salem R.
Combining Transarterial chemoembolization with Radiofrequency Ablation for hepatocellular carcinoma one step forward ? J Clin Oncol.
2013 Vol 31 : 406 – 408.
7- Yamasaki T,
Kurokawa F,
Shirahashi H,
Kusano N,
Hironaka K,
Okita K.
Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood
flow.
Comparison with standard percutaneous radiofrequeucy ablation therapy.
Cancer.
2002,
95 : 2353 – 2360.
8- R lencioni and L.
crocetti.
Image Guided thermal ablation of hepatocellular carcinoma "critical Reviews in Oncology" Hematology.
2008,
vol.
66,
No.
3.
9- Wang YH,
Liu JF,
Li F,
Li A,
Liu Q,
Liu DB,
Liu DG,
Wang YJ.
Radiofrequency ablation combined with transarterial chemoembolization for unresectable primary liver cancer.
Chin Med J (Engl) 2009,
122 (8) :289-894.
10- Altekruse SF,
Mc Glynn kA,
Reichman ME.
Hepatocellular carcinoma incidence,
mortality and survival trends in the United States from 1975 to 2005.
J clin oncol 2009,
27: 1485 : 91.
11- Katayal S,
Oliver JH,
peterson Ms and chang PJ.
Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable HCC,
A Retrospective analysis.
AJR 2002,
175 ; 1995 – 1762.
12- Llovet JM,
Real MI,
Montaña X,
Planas R,
Coll S,
Aponte J,
Ayuso C,
Sala M,
Muchart J,
Solà R,
Rodés J,
Bruix J; Barcelona Liver Cancer Group.
Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: randomized controlled trial.
Lancet.
2002 ,
359 : 1734 – 1739
13- Lo CM,
Ngan H,
Tso WK,
Liu CL,
Lam CM,
Poon RT,
Fan ST,
Wong J.
Randomized controlled trial of transarterial lipidol chemoembolization for unresectable hepatocellular carcinoma.
Hepatology.
2002,
35 : 1164 – 1171 .
14- Takayasu K,
Arii S,
Ikai I,
Omata M,
Okita K,
Ichida T,
Matsuyama Y,
Nakanuma Y,
Kojiro M,
Makuuchi M,
Yamaoka Y;
Liver Cancer Study Group of Japan.
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patient.
Gastroenterology.
2006,
131 : 461 – 469 .
15- Hu HT,
Kim JH,
Lee LS,
Kim KA,
Ko GY,
Yoon HK,
Sung KB,
Gwon DI,
Shin JH,
Song HY.
Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
J vasc Interv Radiol.
2011.
22 : 917 – 923 .
16- Cho YK,
kim MY,
Rhim H,
Han JK.
Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.
Hepatology 2009,
49 (2) : 453 – 459.
17- Veltri A,
Moretto P,
Doriguzzi A,
Pagano E,
Carrara G,
Gandini G.
Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).
Eur Radiol.
2006,
16 (3) : 661 – 665 .
18- Morimoto M,
Numata K,
Kondou M,
Nozaki A,
Morita S,
Tanaka K.
Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization.
Cancer.
2010,
116 : 5452 – 60
19- Peng ZW,
Lin XJ,
Zhang YJ,
Liang HH,
Guo RP,
Shi M,
Chen MS.
Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study.
Radiology.
2012;262(3):1022-1033.
20- Forner A ,
LIvot Jm ,
Bruix J.
Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol.
2012,
56 (4) : 984 – 986.
21- Vivarelli M,
Guglielmi A,
Ruzzenente A,
Cucchetti A,
Bellusci R,
Cordiano C,
Cavallari A.
Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver.
Ann Surg 2004,
240 (1) : 102 – 107.
22- Guglielmi A,
Ruzzenente A,
Valdegamberi A,
Pachera S,
Campagnaro T,
D'Onofrio M,
Martone E,
Nicoli P,
Iacono C.
Radiofrequency ablation versus resection for the treatment of hepatocellular carcinoma in cirrhosis.
J Gastrointest surg.
2008; 12 : 192 – 8.
23- Huang J,
Yan L,
Cheng Z,
Wu H,
Du L,
Wang J,
Xu Y,
Zeng Y.
A randomized trial comparing radiofrequency ablation and surgical resection for HCC confirming to Milan criteria.
Annals of surgery.
2010; 252 : 903 – 912.
24- Lau WY,
Lai EC.
Hepatocellular carcinoma: current management and recent advances.
Hepatobiliary Pancreat Dis Int.
2008; 7 (3) : 237 – 257.
25- Peng ZW,
Chen MS,
Liang HH,
Gao HJ,
Zhang YJ,
Li JQ,
Zhang YQ,
Lau WY.
A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.
Eur J Surg Oncol.
2010;36(3):257-63.
26- Peng ZW,
Zhang YJ,
Liang HH,
Lin XJ,
Guo RP,
Chen MS.
Recurrent Hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus
RF ablation alone : Prospective Randomized Trail.
Radiology.
2012 ;262(2):689-700.
27- Laspas F,
Sotiropoulou E,
Mylona S,
Manataki A,
Tsagouli P,
Tsangaridou I,
Thanos L.
Computed tomography-guided radiofrequency ablation of hepatocellular carcinoma: treatment efficacy and complications.
J Gastro intestine Liver Dis.
2009; 18 (3),
323 – 328.
28- Gasparini D,
Sponza M,
Marzio A,
Zanardi R,
Bazzocchi M,
Cemal Y.
Combined treatment,
TACE and RF ablation,
in HCC: preliminary results.
Radiol Med.
2002;104(5-6):412-20.
29- Liapi E,
Geschwind JF.
Medium-sized HCC: achieving effective local tumor control with combined chemoebolization and radiofrequency ablation.
Ann Surg Oncol.
2011; 18 : 1527 – 1528.
30- Kudo M.
Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010.
Oncology.
2010 Jul;78 Suppl 1:113-24.